 Stephanie Gardner
Concepts (216)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 3 | 2012 | 146 | 0.860 |
Why?
| | Rural Health Services | 2 | 2024 | 168 | 0.820 |
Why?
| | Curriculum | 5 | 2012 | 398 | 0.740 |
Why?
| | Students, Pharmacy | 4 | 2010 | 124 | 0.640 |
Why?
| | Schools, Pharmacy | 2 | 2010 | 53 | 0.640 |
Why?
| | Blood Pressure | 8 | 2008 | 529 | 0.590 |
Why?
| | Telemedicine | 1 | 2024 | 468 | 0.570 |
Why?
| | Dental Caries | 1 | 2016 | 8 | 0.520 |
Why?
| | Schools, Dental | 1 | 2016 | 7 | 0.520 |
Why?
| | Tetrazoles | 2 | 2008 | 40 | 0.510 |
Why?
| | Hypertension | 5 | 2008 | 550 | 0.450 |
Why?
| | Dietary Supplements | 7 | 2005 | 445 | 0.390 |
Why?
| | Faculty | 2 | 2010 | 72 | 0.390 |
Why?
| | Pharmacy | 1 | 2012 | 54 | 0.370 |
Why?
| | Plant Preparations | 5 | 2005 | 39 | 0.370 |
Why?
| | Career Choice | 1 | 2012 | 111 | 0.370 |
Why?
| | Patient Care Team | 2 | 2003 | 258 | 0.360 |
Why?
| | Antihypertensive Agents | 3 | 2003 | 127 | 0.350 |
Why?
| | Arkansas | 5 | 2024 | 1991 | 0.320 |
Why?
| | Biphenyl Compounds | 1 | 2008 | 31 | 0.310 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 43 | 0.300 |
Why?
| | School Admission Criteria | 1 | 2008 | 35 | 0.300 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2003 | 201 | 0.300 |
Why?
| | Benzimidazoles | 1 | 2008 | 49 | 0.300 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 6 | 2008 | 36 | 0.300 |
Why?
| | Ephedrine | 5 | 2003 | 21 | 0.300 |
Why?
| | Clinical Competence | 2 | 2010 | 397 | 0.300 |
Why?
| | Delivery of Health Care | 2 | 2024 | 308 | 0.290 |
Why?
| | Niacin | 2 | 1997 | 5 | 0.280 |
Why?
| | Intergenerational Relations | 1 | 2006 | 4 | 0.270 |
Why?
| | Humans | 37 | 2024 | 50389 | 0.270 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2004 | 516 | 0.270 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2004 | 19 | 0.270 |
Why?
| | Students | 2 | 2023 | 222 | 0.270 |
Why?
| | Probucol | 1 | 2005 | 3 | 0.260 |
Why?
| | Coronary Restenosis | 1 | 2005 | 31 | 0.250 |
Why?
| | Interprofessional Relations | 1 | 2006 | 84 | 0.250 |
Why?
| | Angiotensin II | 2 | 2004 | 162 | 0.240 |
Why?
| | Alkaloids | 3 | 2000 | 29 | 0.240 |
Why?
| | Hospitals, Rural | 1 | 2024 | 15 | 0.230 |
Why?
| | Phytotherapy | 2 | 2003 | 42 | 0.230 |
Why?
| | Ephedra | 1 | 2003 | 8 | 0.220 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2003 | 23 | 0.220 |
Why?
| | Rural Health | 1 | 2024 | 89 | 0.220 |
Why?
| | Hemostasis | 1 | 2003 | 56 | 0.210 |
Why?
| | Self Care | 1 | 2003 | 136 | 0.200 |
Why?
| | Community Pharmacy Services | 1 | 2003 | 66 | 0.200 |
Why?
| | Administrative Personnel | 1 | 2002 | 13 | 0.200 |
Why?
| | Ephedra sinica | 2 | 1998 | 2 | 0.200 |
Why?
| | Imidazoles | 1 | 2003 | 128 | 0.200 |
Why?
| | Education, Medical, Undergraduate | 1 | 2002 | 83 | 0.180 |
Why?
| | Academic Medical Centers | 1 | 2002 | 147 | 0.180 |
Why?
| | Patient Education as Topic | 1 | 2003 | 317 | 0.180 |
Why?
| | Male | 21 | 2023 | 25718 | 0.180 |
Why?
| | Rural Population | 1 | 2024 | 552 | 0.160 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2004 | 326 | 0.160 |
Why?
| | Cytochrome P-450 Enzyme System | 3 | 2005 | 194 | 0.160 |
Why?
| | Hypercholesterolemia | 2 | 1997 | 37 | 0.160 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 349 | 0.150 |
Why?
| | Female | 20 | 2023 | 26981 | 0.150 |
Why?
| | Erectile Dysfunction | 1 | 1999 | 87 | 0.150 |
Why?
| | Pravastatin | 1 | 1997 | 18 | 0.140 |
Why?
| | Primary Health Care | 1 | 2001 | 364 | 0.140 |
Why?
| | Anticholesteremic Agents | 1 | 1997 | 28 | 0.140 |
Why?
| | Adult | 14 | 2023 | 13568 | 0.140 |
Why?
| | Heart Rate | 5 | 2003 | 311 | 0.140 |
Why?
| | Sodium | 2 | 1996 | 91 | 0.130 |
Why?
| | Lovastatin | 1 | 1996 | 9 | 0.130 |
Why?
| | Hypolipidemic Agents | 1 | 1996 | 28 | 0.130 |
Why?
| | Erythromycin | 1 | 1996 | 10 | 0.130 |
Why?
| | Torsades de Pointes | 1 | 1996 | 15 | 0.130 |
Why?
| | Hyperlipidemias | 1 | 1996 | 52 | 0.130 |
Why?
| | Polyethylene Glycols | 1 | 1995 | 86 | 0.120 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 378 | 0.120 |
Why?
| | Pharmacies | 1 | 1995 | 60 | 0.110 |
Why?
| | Pilot Projects | 2 | 2008 | 704 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2008 | 1356 | 0.110 |
Why?
| | Aged | 10 | 2008 | 9590 | 0.110 |
Why?
| | Clinical Trials as Topic | 3 | 2005 | 465 | 0.110 |
Why?
| | Middle Aged | 10 | 2008 | 12460 | 0.100 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 49 | 0.100 |
Why?
| | Tomography, Emission-Computed | 1 | 1992 | 53 | 0.100 |
Why?
| | Education, Pharmacy, Continuing | 1 | 1991 | 4 | 0.100 |
Why?
| | Accreditation | 1 | 1991 | 60 | 0.090 |
Why?
| | Education, Medical, Continuing | 1 | 1991 | 68 | 0.090 |
Why?
| | Organizational Policy | 1 | 2010 | 38 | 0.090 |
Why?
| | Pharmacists | 1 | 1991 | 145 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 1996 | 745 | 0.090 |
Why?
| | Social Environment | 1 | 2010 | 79 | 0.090 |
Why?
| | Plant Extracts | 2 | 2004 | 166 | 0.090 |
Why?
| | Heart Failure | 1 | 1995 | 526 | 0.080 |
Why?
| | Drug Interactions | 4 | 2004 | 208 | 0.080 |
Why?
| | Phenotype | 4 | 2005 | 736 | 0.080 |
Why?
| | Misoprostol | 1 | 2008 | 5 | 0.080 |
Why?
| | Diclofenac | 1 | 2008 | 9 | 0.080 |
Why?
| | Drug Therapy, Combination | 3 | 2004 | 383 | 0.080 |
Why?
| | Sodium Chloride | 1 | 2008 | 58 | 0.080 |
Why?
| | Blood Glucose | 2 | 2003 | 443 | 0.070 |
Why?
| | Guidelines as Topic | 1 | 2008 | 110 | 0.070 |
Why?
| | Adolescent | 3 | 2023 | 6475 | 0.070 |
Why?
| | Guideline Adherence | 1 | 2008 | 133 | 0.070 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 122 | 0.070 |
Why?
| | Drugs, Investigational | 1 | 2005 | 14 | 0.060 |
Why?
| | Valerian | 1 | 2005 | 2 | 0.060 |
Why?
| | Cimicifuga | 1 | 2005 | 8 | 0.060 |
Why?
| | Kava | 1 | 2005 | 11 | 0.060 |
Why?
| | Hydrastis | 1 | 2005 | 10 | 0.060 |
Why?
| | Educational Measurement | 1 | 2007 | 205 | 0.060 |
Why?
| | Citrus | 1 | 2004 | 5 | 0.060 |
Why?
| | Echinacea | 1 | 2004 | 5 | 0.060 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 74 | 0.060 |
Why?
| | Molecular Structure | 1 | 2005 | 293 | 0.060 |
Why?
| | Cognition | 1 | 2007 | 314 | 0.060 |
Why?
| | Prospective Studies | 3 | 2008 | 2414 | 0.060 |
Why?
| | Antioxidants | 1 | 2005 | 238 | 0.060 |
Why?
| | Kidney | 1 | 2008 | 686 | 0.060 |
Why?
| | Central Nervous System Stimulants | 2 | 2004 | 205 | 0.050 |
Why?
| | Cost Savings | 1 | 2003 | 58 | 0.050 |
Why?
| | Diastole | 1 | 2003 | 70 | 0.050 |
Why?
| | Bradycardia | 1 | 2003 | 37 | 0.050 |
Why?
| | Systole | 1 | 2003 | 72 | 0.050 |
Why?
| | Receptors, Angiotensin | 1 | 2003 | 13 | 0.050 |
Why?
| | Prescription Fees | 1 | 2003 | 14 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2023 | 92 | 0.050 |
Why?
| | Tachycardia, Ventricular | 1 | 2003 | 45 | 0.050 |
Why?
| | Plants, Medicinal | 2 | 2000 | 35 | 0.050 |
Why?
| | Health Services Research | 1 | 2003 | 150 | 0.050 |
Why?
| | Reference Values | 1 | 2003 | 312 | 0.050 |
Why?
| | Mixed Function Oxygenases | 1 | 2002 | 25 | 0.050 |
Why?
| | Amphetamines | 1 | 2002 | 27 | 0.050 |
Why?
| | Kidney Diseases | 1 | 2004 | 213 | 0.050 |
Why?
| | Universities | 1 | 2023 | 170 | 0.050 |
Why?
| | Time Factors | 3 | 2005 | 2934 | 0.050 |
Why?
| | Program Evaluation | 1 | 2003 | 349 | 0.050 |
Why?
| | Cytochrome P-450 CYP2E1 | 1 | 2002 | 110 | 0.050 |
Why?
| | Models, Educational | 1 | 2002 | 30 | 0.050 |
Why?
| | Patient Compliance | 1 | 2003 | 231 | 0.050 |
Why?
| | Sympathomimetics | 2 | 1998 | 21 | 0.050 |
Why?
| | Methylphenidate | 1 | 2002 | 75 | 0.050 |
Why?
| | Body Weight | 1 | 2003 | 514 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2023 | 709 | 0.050 |
Why?
| | Midazolam | 3 | 2005 | 37 | 0.050 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2002 | 173 | 0.040 |
Why?
| | Caffeine | 3 | 2005 | 64 | 0.040 |
Why?
| | Herb-Drug Interactions | 3 | 2005 | 31 | 0.040 |
Why?
| | Body Mass Index | 1 | 2003 | 669 | 0.040 |
Why?
| | Plants, Toxic | 1 | 1999 | 10 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2001 | 386 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 1998 | 110 | 0.040 |
Why?
| | Child | 2 | 2008 | 6877 | 0.040 |
Why?
| | Fructosamine | 1 | 1997 | 1 | 0.040 |
Why?
| | Lipoprotein(a) | 1 | 1997 | 6 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 1997 | 38 | 0.040 |
Why?
| | Drugs, Chinese Herbal | 1 | 1997 | 5 | 0.040 |
Why?
| | Cross-Over Studies | 3 | 2008 | 224 | 0.030 |
Why?
| | Comorbidity | 1 | 1999 | 617 | 0.030 |
Why?
| | United States | 2 | 2002 | 4913 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 1590 | 0.030 |
Why?
| | Nifedipine | 1 | 1996 | 25 | 0.030 |
Why?
| | Pancreas Transplantation | 1 | 1996 | 22 | 0.030 |
Why?
| | Ethanol | 1 | 1999 | 336 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 1996 | 64 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 1996 | 89 | 0.030 |
Why?
| | Pharmaceutical Vehicles | 1 | 1995 | 3 | 0.030 |
Why?
| | Models, Biological | 1 | 1999 | 723 | 0.030 |
Why?
| | Electrolytes | 1 | 1995 | 27 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 1998 | 1201 | 0.030 |
Why?
| | Kidney Transplantation | 1 | 1996 | 182 | 0.030 |
Why?
| | Isoenzymes | 2 | 2005 | 168 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2005 | 369 | 0.030 |
Why?
| | Ginkgo biloba | 2 | 2005 | 7 | 0.030 |
Why?
| | Panax | 2 | 2005 | 6 | 0.030 |
Why?
| | Allyl Compounds | 2 | 2005 | 11 | 0.030 |
Why?
| | Hypericum | 2 | 2005 | 13 | 0.030 |
Why?
| | Electrocardiography | 1 | 1996 | 267 | 0.030 |
Why?
| | Sulfides | 2 | 2005 | 28 | 0.030 |
Why?
| | Critical Care | 1 | 1996 | 215 | 0.030 |
Why?
| | Young Adult | 1 | 2023 | 4064 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2003 | 5230 | 0.030 |
Why?
| | Mass Screening | 1 | 1995 | 348 | 0.020 |
Why?
| | Databases, Factual | 1 | 1995 | 667 | 0.020 |
Why?
| | Specialty Boards | 1 | 1991 | 24 | 0.020 |
Why?
| | Capsules | 2 | 2005 | 28 | 0.020 |
Why?
| | Public Policy | 1 | 1991 | 38 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2003 | 6223 | 0.020 |
Why?
| | Animals | 1 | 2005 | 13173 | 0.020 |
Why?
| | Data Collection | 1 | 1991 | 283 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 1996 | 3180 | 0.020 |
Why?
| | Sex Factors | 2 | 2002 | 702 | 0.020 |
Why?
| | Risk Factors | 1 | 1995 | 3692 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2008 | 682 | 0.020 |
Why?
| | Chlorzoxazone | 1 | 2005 | 5 | 0.020 |
Why?
| | Debrisoquin | 1 | 2004 | 1 | 0.020 |
Why?
| | Serenoa | 1 | 2004 | 7 | 0.020 |
Why?
| | GABA Modulators | 1 | 2004 | 9 | 0.010 |
Why?
| | Adrenergic Agents | 1 | 2004 | 15 | 0.010 |
Why?
| | Solubility | 1 | 2004 | 72 | 0.010 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 74 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 432 | 0.010 |
Why?
| | Patient Selection | 1 | 2005 | 257 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 635 | 0.010 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2002 | 77 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2002 | 562 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 180 | 0.010 |
Why?
| | Drug Labeling | 1 | 2000 | 11 | 0.010 |
Why?
| | Drug and Narcotic Control | 1 | 2000 | 10 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 934 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1997 | 69 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 85 | 0.010 |
Why?
| | Compartment Syndromes | 1 | 1996 | 16 | 0.010 |
Why?
| | Area Under Curve | 1 | 1997 | 179 | 0.010 |
Why?
| | Delayed-Action Preparations | 1 | 1996 | 55 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 1996 | 76 | 0.010 |
Why?
| | Dopamine | 1 | 1996 | 171 | 0.010 |
Why?
| | Regression Analysis | 1 | 1996 | 396 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 1996 | 223 | 0.010 |
Why?
|
|
Gardner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|